ClinicalTrials.gg
CompletedNCT05128591Updated Mar 8, 2022

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

A Phase 1 interventional study of Rivaroxaban 18mg Oral Tablet and Rivaroxaban 20 MG Oral Tablet in Embolism and Thrombosis, sponsored by Addpharma Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-08.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

Read the detailed description

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-109 compared with AD-1091 in healthy male subjects.

02

Conditions studied

  • Embolism and Thrombosis
03

In context

Embolism and Thrombosis

53 studies on the registry are indexed under Embolism and Thrombosis; 11 are open to participants now.

This study's enrollment of 38 is below the median of 252 across 28 interventional studies indexed under Embolism and Thrombosis.

Browse Embolism and Thrombosis studies →

Lead sponsor

Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.

First submitted after Addpharma Inc. became part of Yuhan Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight equal to or greater than 50kg and (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 in healthy male volunteers at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Patients with Medical history increasing the risk of bleeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Arm A-Rivaroxaban

    Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)

    Drug: Rivaroxaban 18mg Oral Tablet · Drug: Rivaroxaban 20 MG Oral Tablet

  • Experimental
    Arm B-Rivaroxaban

    Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091

    Drug: Rivaroxaban 18mg Oral Tablet · Drug: Rivaroxaban 20 MG Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Cmax of Rivaroxaban

    Time frame: pre-dose to 34 hours

  2. Area Under the Curve in time plot (AUCt)

    AUCt of Rivaroxaban

    Time frame: pre-dose to 34 hours

07

Study locations

1 site
  • H+ Yangji Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Nov 22, 2021
StartActual
Nov 9, 2021
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Last update
Mar 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05128591
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Nov 9, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Mar 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion